Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Lymphoma-Derived IL-10 Is a Key Immunomodulatory Factor at the Tumor Microenvironment of Activated B-Cell Diffuse Large B-Cell Lymphoma and Influences In Vivo Responses to Immunotherapy

Marcos Garcia-Lacarte, Sara C Grijalba, Francisco J Novo, Adrián Arnaiz-Leché, Javier Melchor, Marién Pascual, Enrique Goñi, Sandra Morales-Sánchez, María A Burrell, Oscar Blanco, Iñigo Clemente-Larramendi, Jose A Martinez-Climent, Noelia Casares, Juan J Lasarte, Pablo Sarobe, Miguel Canales, Sergio Roa

Blood (2023) 142 (Supplement 1): 716.

https://doi.org/10.1182/blood-2023-177612

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

Jon Celay, Miriam Recalde, María Victoria Revuelta, Marta Larrayoz, Sara Rodriguez, Maria J Garcia-Barchino, Jennifer R. Chapman-Fredricks, Teresa Lozano, Juan J Lasarte, Ming Q. Du, Izidore S. Lossos, Sergio Roa, Aldo Roccaro, Miguel Canales, Felipe Prosper, Bruno Paiva, Leandro Cerchietti, Jose A. Martinez-Climent

Blood (2023) 142 (Supplement 1): 431.

https://doi.org/10.1182/blood-2023-173394

Published: 2023

Journal Articles

A Multi-Omic Study Unveils a Clonal Population of TET2-Mutated Infiltrating T-Cells in Germinal Center B Cell Lymphomas (DLBCL and FL)

Sofia Huerga, Beñat Ariceta, Paula Aguirre-Ruiz, Patxi San-Martin, Sarai Sarvide, Marta Abengozar-Muela, Diego Alignani, Rocio Figueroa, Carlos Grande, Alvaro Lopez-Janeiro, Emma Muiños-Lopez, Juan Roberto Rodriguez-Madoz, Amaia Vilas-Zornoza, Felipe Prosper, Miguel Canales

Blood (2023) 142 (Supplement 1): 3003.

https://doi.org/10.1182/blood-2023-182830

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Blood (2022) 140 (Supplement 1): 1471–1473.

https://doi.org/10.1182/blood-2022-158232

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde

Blood (2022) 140 (Supplement 1): 1467–1470.

https://doi.org/10.1182/blood-2022-157691

Published: 2022

Journal Articles

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 3514–3515.

https://doi.org/10.1182/blood-2022-166372

Published: 2022

Journal Articles

Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests

Paula Acuña, Elena Monzón Manzano, Elena G Arias-Salgado, María Teresa Alvarez Román, Mónica Martín, María Isabel Rivas Pollmar, Víctor Jiménez-Yuste, Miguel Canales, Nora V. Butta

Blood (2021) 138 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2021-151203

Published: 2021

Journal Articles

Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia

Elena Monzón Manzano, María Teresa Alvarez Román, Andres Ramirez Lopez, Elena G Arias-Salgado, Paula Acuña, Mónica Martín, María Isabel Rivas Pollmar, Sara García Barcenilla, Tamara Cebanu, Miguel Canales, Víctor Jiménez-Yuste, Nora V. Butta

Blood (2021) 138 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2021-153425

Published: 2021

Journal Articles

Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency

Elena G Arias-Salgado, María Isabel Rivas Pollmar, Elena Monzón Manzano, Paula Acuña, María Teresa Alvarez Román, Mónica Martín, Sara García Barcenilla, Tamara Cebanu, Nuria Díaz Blazquez, Miguel Canales, Nora V. Butta, Víctor Jiménez-Yuste

Blood (2021) 138 (Supplement 1): 1046.

https://doi.org/10.1182/blood-2021-153243

Published: 2021

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Ryan C. Lynch, Abraham Avigdor, Matthew S McKinney, Shankara Paneesha, Björn Wahlin, John S Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J DeMarini, Wei Jiang, Marek Trněný

Blood (2021) 138 (Supplement 1): 813.

https://doi.org/10.1182/blood-2021-147918

Published: 2021

Journal Articles

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Blood (2021) 138 (Supplement 1): 1420.

https://doi.org/10.1182/blood-2021-150025

Published: 2021

Journal Articles

Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia

Nora V. Butta, Stuart M Haslam, Anne Dell, Leow Ke Xuan, Sophie Ball, Elena G Arias-Salgado, Elena Monzón Manzano, Paula Acuña, Miguel Canales, Víctor Jiménez-Yuste, María Teresa Alvarez Román

Blood (2021) 138 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2021-150771

Published: 2021

Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2021-147937

Published: 2021

Journal Articles

Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma

Peter Trask, Jaisson Bortolini, Shinya Rai, Antonio Salar, Miguel Canales, Dirk Klingbiel, Joana Parreira, Maud Deraet, Ekaterina Vorozheikina, Kai Hübel, Thomas Buchholz

Blood (2021) 138 (Supplement 1): 1345.

https://doi.org/10.1182/blood-2021-147911

Published: 2021

Journal Articles

Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH

Blood (2021) 138 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2021-152376

Published: 2021

Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 127.

https://doi.org/10.1182/blood-2021-145872

Published: 2021

Journal Articles

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Adam J Olszewski, MD, Javier Munoz, MD, Tae Min Kim, MD PhD, Dok Hyun Yoon, Richard Greil, MD, Jason Westin, MD, Ulrich Jaeger, Miguel Canales, Cindy Chen, Betsy Althaus, Carol O'Hear, Raluca Negricea, Yuying Xie, Ronald McCord, Enkhtsetseg Purev, Anusha Vallurupalli

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-136295

Published: 2020

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Ryan C. Lynch, MD, Shankara Paneesha, MD, Abraham Avigdor, MD, Matthew S McKinney, Björn E Wahlin, MD PhD, John S Hrom, David Belada, MD PhD, Miguel Canales, David Cunningham, MD FRCP, FMedSci, Liliana Devizzi, Nicholas Morley, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Marek Trněný, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134869

Published: 2020

NARROW

Lymphoma-Derived IL-10 Is a Key Immunomodulatory Factor at the Tumor Microenvironment of Activated B-Cell Diffuse Large B-Cell Lymphoma and Influences In Vivo Responses to Immunotherapy

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas

A Multi-Omic Study Unveils a Clonal Population of TET2-Mutated Infiltrating T-Cells in Germinal Center B Cell Lymphomas (DLBCL and FL)

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests

Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia

Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma

Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only